Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP1902 vs RLD2007/RLD2008 in Healthy Volunteers
NCT04946903Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Jun 2021; status: completed.
02
Drugs
sitagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04946903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946903.